{
    "clinical_study": {
        "@rank": "62069", 
        "arm_group": [
            {
                "arm_group_label": "5mg sublingual Zolpidem hemitartrate", 
                "arm_group_type": "Experimental", 
                "description": "1 QD"
            }, 
            {
                "arm_group_label": "10 mg oral Zolpidem hemitartrate", 
                "arm_group_type": "Active Comparator", 
                "description": "1 QD."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of sublingual zolpidem\n      presentation 5 mg in the induction of sleep in patients with primary insomnia."
        }, 
        "brief_title": "Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Insomnia", 
        "condition_browse": {
            "mesh_term": "Sleep Initiation and Maintenance Disorders"
        }, 
        "detailed_description": {
            "textblock": "-  National study, phase IV, single-center, double-blind, randomized, parallel, controlled\n           by zolpidem 10mg oral.\n\n        -  Experiment duration: 93 days.\n\n        -  05 visits (days -3, 0, 15, 45 and 90).\n\n        -  Efficacy will be evaluated for: Sleep induction and the maintenance of sleep.\n\n        -  Adverse events evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women aged between 20 and 64 years;\n\n          -  Diagnosis of primary insomnia according to criteria defined by DSM-IV;\n\n          -  Difficulty in maintaining sleep and waking up until 3 am;\n\n          -  Not having used any psychoactive drug in the last 30 days prior to their inclusion in\n             the study;\n\n          -  Signature of IC.\n\n        Exclusion Criteria:\n\n          -  Previous history of serious medical illness, neurological or psychiatric disorder;\n\n          -  Allergy or hypersensitivity to zolpidem;\n\n          -  Obstructive Sleep Apnea syndrome;\n\n          -  Polysomnography with apnea and hypopnea index >10/hour or PLM >15/h;\n\n          -  Other secondary sleep disorders;\n\n          -  History of substance abuse or dependence;\n\n          -  History of daily consumption of alcoholic beverages;\n\n          -  Pregnancy, lactation or refusal to use safe contraceptive methods during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896336", 
            "org_study_id": "ZPDEMS1011"
        }, 
        "intervention": {
            "arm_group_label": [
                "5mg sublingual Zolpidem hemitartrate", 
                "10 mg oral Zolpidem hemitartrate"
            ], 
            "description": "Patz - 5mg sublingual zolpidem hemitartrate\n1 QD\nStilnox - 10mg oral zolpidem hemitartrate\n1 QD", 
            "intervention_name": "Zolpidem Hemitartrate", 
            "intervention_type": "Drug", 
            "other_name": [
                "Patz - 5mg sublingual zolpidem hemitartrate", 
                "Stilnox - 10mg oral zolpidem hemitartrate"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Zolpidem"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "state": "S\u00e2o Paulo", 
                    "zip": "04020-060"
                }, 
                "name": "AFIP"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "National Study, Phase IV, Single-center, Double-blind, Randomized, Parallel, Controlled by 10 mg Oral Zolpidem, in Evaluating the Efficacy and Safety of Zolpidem 5 mg Sublingual in the Induction and Maintenance of Sleep in Patients With Primary Insomnia", 
        "overall_official": {
            "affiliation": "Associacao Fundo de Incentivo a Psicofarmcologia", 
            "last_name": "Dalva R Poyares, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Sleep induction is measured by time to sleep after administration of the investigational product.\nThe maintenance will be measured by the use of medication in the middle of the night and also by the elapsed time to sleep after administration of the investigational drug.", 
            "measure": "Efficacy will be measured by sleep induction and maintenance.", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events will be collected and followed in order to evaluate safety and tolerability", 
            "measure": "Safety will be evaluated by the adverse events occurrences", 
            "safety_issue": "Yes", 
            "time_frame": "90 days"
        }, 
        "source": "EMS", 
        "sponsors": {
            "collaborator": {
                "agency": "Associa\u00e7\u00e3o Fundo de Incentivo \u00e0 Pesquisa", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "EMS", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}